This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
miLab Platform ProductsImprove diagnostic workflows
Improve diagnostic workflows
and accessibility at once
Beyond DiagnosticsWe provide products and services that impact
We provide products and services that impact
one billion people's life in the world.
Noul focuses on the most challenging healthcare issues the world has yet to resolve.
We deliver innovative diagnostic solutions in blood and tissue diagnostics dramatically improve medical access and
conquer cancer.
Our Story in Numbers
- NVIDIA GTC selected AI Startups
- Top 0
- Cumulative investment (USD)
- 0million
- Annual sales growth (as of 2023)
- 0%
We continues to grow, moving toward the next stage.
- Patent registrations and applications
- 0cases, 0cases
- Cumulative orders for National R&D project (USD)
- 0million
- Researcher in company
- 0%
We creates innovation based on R&D and technology patents.
- Countries using miLab™
- 0countries
- Cumulative diagnosis using miLab™
- 0diagnoses
- Partner organizations
- 0+
miLab™ Solution leads the global blood and cancer diagnosis.
- Digitalize entire process (stain, scan, AI analyze)
- All inOne
- Time required for diagnosis (more than 2x improvement)
- Avg0mins
- Accuracy of test results (Based on miLab™ MAL)
- Sensitivity0% ,
Specificity0%
miLab™ Solution has dramatically improved the diagnostic process.
Noul Highlights
Find our latest news
View More-
AI-Powered CBC Analyzer for Mexico: NOUL and Nihon Kohden Introduce miLab™ BCM Table of Contents Toggle Current State of Blood Diagnostics in Mexican Healthcare… Read MoreBlog | 2025.06.26
-
Noul Sustainability Report 2024-2025 Since 2020, Noul has published an annual sustainability report in accordance with its Articles of Incorporation, to transparently communicate its business activities and performance across economic, social, and environmental dimensions to stakeholders. The 2024–2025 Sustainability Report highlights Noul’s key initiatives and outcomes in its scale-up phase, including business expansion… Read MoreNews | 2025.06.20
-
AI-Powered Cervical Cancer Screening Solutions for Central America Table of Contents Toggle How Central America is Addressing the Global Health Concern… Read MoreBlog | 2025.06.19
-
AI Blood Diagnostics in Kuwait: miLab™ and the Future of National Screening Table of Contents Toggle Rapidly Growing Demand for Blood Diagnostics in Kuwait’s Healthcare Landscape… Read MoreBlog | 2025.06.12
-
Zero Malaria Progress in Africa: Updates from Guinea, Botswana, Ethiopia, and Beyond Table of Contents Toggle Supporting Africa’s Zero Malaria Initiative: NOUL’s Commitment… Read MoreBlog | 2025.06.05
-
Next-Generation Blood Testing for Europe’s Point-of-Care Future Table of Contents Toggle Core of Europe’s POC Diagnostics Market: Blood Testing… Read MoreBlog | 2025.05.29
- Career Join our team, committed to
making a positive impact - View More
- Sustainability at Noul Sustainability is
at the core of our business philosophy. - Sustainability
